Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 2, 2012
Event: Agreement in principle to settle litigation filed in 2002 in the U.S. District Court, Eastern District of Texas, regarding federal program claims about historical Epogen practices dating back to 1997.
Key Financial Metrics
- Settlement Payment: $55 million plus attorneys' fees.
- Q2 2012 Charge: Approximately $78 million (includes settlement and related expenses).
- Revenue, Profit, Cash Flow, Debt, Liquidity: The filing text does not provide clear values for these general financial metrics; it focuses solely on the litigation settlement impact.
Material Changes
The primary material change is the anticipated non-recurring charge of approximately $78 million to be recorded in the second quarter of 2012 results. This charge reflects the resolution of long-standing allegations related to Epogen practices.
Outlook, Risks, and Contingencies
- Conditions Precedent: The settlement is subject to court approval and the completion of certain conditions and documentation.
- Uncertainty: Until conditions are met, there is no assurance the matter will be resolved pursuant to the settlement terms.
- Scope: Expected to resolve federal program claims regarding Epogen that were or could have been raised in the 2002 complaint.
Investor Verification Checklist
- Confirm the final court approval status of the $55 million settlement plus fees.
- Verify the exact composition of the $78 million Q2 charge in the upcoming earnings release.
- Review the attached Press Release (Exhibit 99.1) for additional details on the settlement terms.
- Monitor for any updates on the resolution of the 2002 Eastern District of Texas litigation.